uniQure ($QURE): 80% cUHDRS Slowing at 36 Months for AMT-130 — What Do the 48-Month Data Change?

01 Bull, base and bear scenarios

September 29, 2026 update. The scenarios below must now incorporate a known, mixed durability result. The constructive path requires the regulators to find the overall evidence and confirmatory program sufficient despite the non-significant 48-month primary endpoint. The central unresolved case is a review with substantial questions about missing data and comparator selection. The adverse path includes additional-evidence requirements, delay or an unfavorable regulatory decision. None is established by the September 29 release. Company source

Bull scenario

uniQure aligns with FDA on a feasible confirmatory study, sees the BLA accepted for filing, receives priority review and avoids a damaging advisory-committee outcome. FDA grants accelerated approval based on the three-year dataset. Treatment centers activate quickly, early manifest patients accept the procedure and real-world follow-up supports durable slowing. AMT-260 produces multi-patient seizure reductions and AMT-191 identifies a safe effective dose.

Base scenario

The BLA is submitted but review is contentious. FDA accepts the filing while asking for stronger confirmatory-study execution, longer follow-up or more CMC work. Approval remains possible but the timeline slips. AMT-260 remains promising but immature; AMT-191 is constrained by liver toxicity. Cash remains sufficient, but the stock trades almost entirely on regulatory headlines.

Bear scenario

uniQure fails to finalize an acceptable confirmatory design or FDA again changes its interpretation. The BLA is refused for filing or rejected. Longer-term AMT-130 data weaken versus natural history, or a new neurological safety issue appears. Launch spending and confirmatory work consume cash while secondary programs fail to create offsetting value.

What Would Change This Assessment

The application relies on externally controlled evidence with supportive 36-month findings and an inconclusive 48-month primary analysis. These developments would test the regulatory, clinical and funding assumptions; none alone fixes the eventual outcome.

• Regulatory evidence requirements. A refusal to file or request for additional controlled evidence could alter the current path; submission-basis feedback is not a final benefit-risk decision.
• Confirmatory-study execution. Delayed alignment, site activation or recruitment could affect whether the study meets FDA’s expectations at a potential approval date.
• Longer follow-up. Further weakening of treatment-control separation would require reassessing durability and comparator missingness together, rather than attributing the change automatically to either treatment failure or survivor bias.
• Funding requirements. June liquidity supports management’s plan; a larger trial, extended delay or different launch budget could change spending and future financing needs. Equity issuance alone does not prove the plan has failed.

These conditional tests are not predictions of regulatory decisions or share-price outcomes.

02 Company profile: from HEMGENIX pioneer to AMT-130 special situation

uniQure is one of the longest-established publicly traded gene-therapy companies. The company built its scientific identity around adeno-associated viral vectors, internal manufacturing, liver-directed gene delivery and later direct-to-brain administration. Its history includes Glybera, the first gene therapy approved in Europe, and etranacogene dezaparvovec, now commercialized by CSL Behring as HEMGENIX for hemophilia B.

Beyond AMT-130, uniQure has two active clinical programs with independent value: AMT-260 for refractory mesial temporal lobe epilepsy and AMT-191 for Fabry disease. AMT-162 in SOD1-ALS was discontinued after a dose-limiting toxicity and an unfavorable review of preliminary safety and efficacy. The discontinuation shows that uniQure is willing to terminate a program, but also reinforces the platform-wide reality that CNS and systemic AAV programs can encounter serious safety limits.

03 Current pipeline snapshot

AMT-130 dominates the current regulatory case. AMT-260 remains early and heterogeneous; AMT-191 requires dose and safety resolution. AMT-162 is discontinued.

04 Huntington’s disease and the unmet need

Huntington’s disease is an inherited, progressive neurodegenerative disorder caused by an expanded CAG repeat in the HTT gene. The mutation produces toxic forms of huntingtin protein, including mutant huntingtin and exon 1 fragments, that impair neuronal function and eventually drive widespread brain degeneration.

Patients may develop chorea, rigidity, impaired coordination, cognitive decline, psychiatric symptoms and loss of functional independence. Because the mutation is autosomal dominant, children of an affected parent have a 50% chance of inheriting it. Genetic testing can identify mutation carriers years or decades before overt disease.

Available therapies are symptomatic. They can reduce chorea, depression, irritability or other manifestations, but they do not clearly slow the underlying neurodegenerative process. This is why a credible disease-modifying effect can carry enormous clinical and commercial value even if the treatment requires a complex neurosurgical procedure.

The challenge is measurement. Huntington’s progresses slowly and heterogeneously. Short studies may not cleanly distinguish treatment effect from natural variability. Composite measures such as the composite Unified Huntington’s Disease Rating Scale combine motor, cognitive and functional domains, but interpreting an uncontrolled or externally controlled study requires careful matching and sensitivity analyses.

05 How AMT-130 works

AMT-130 is a one-time investigational gene therapy delivered directly into the striatum through MRI-guided neurosurgical infusion. The product uses an AAV5 vector carrying a microRNA designed to reduce expression of the huntingtin gene. The goal is durable lowering of both full-length huntingtin and the highly toxic exon 1 fragment in brain regions central to Huntington’s pathology.

The therapy does not distinguish between mutant and wild-type huntingtin. That creates a core biological trade-off. Lowering mutant huntingtin could slow disease, but excessive suppression of normal huntingtin may create theoretical or long-term risks because the normal protein has important cellular functions. Dose selection must therefore balance sufficient knockdown with preservation of safety.

Direct striatal administration is both a strength and a weakness. It places therapy in the region most affected early in Huntington’s and may support broad brain distribution through vector transport and exosome-mediated spread. But it requires specialized neurosurgery, bilateral catheter placement, hospital resources and post-procedure monitoring. The commercial model would resemble a small number of expert treatment centers rather than conventional outpatient prescribing.

One-time administration

Potential durability can reduce the burden of repeated intrathecal or systemic dosing.

Direct brain delivery

Targets key pathology but creates surgical risk, logistical complexity and a narrow center network.

Non-allele-selective lowering

May achieve broad huntingtin suppression but requires long-term monitoring of normal HTT reduction.

06 The Phase I/II program: U.S. and European studies

September 29, 2026 update. The new analysis uses a June 30, 2026 cutoff. The first two cohorts contain 29 treated patients: 17 at high dose and 12 at low dose. Follow-up availability differs: 15 high-dose patients contribute at 36 months and 12 at 48 months. The wider clinical program has treated 51 patients across additional cohorts and crossovers; that total is not the denominator of the 48-month efficacy analysis. Company source

The AMT-130 development program combines U.S. and European Phase I/II studies in patients with early manifest Huntington’s disease. The U.S. trial enrolled low-dose and high-dose cohorts with imitation-surgery controls, while the European study used an open-label design. Control participants in the U.S. study could cross over to active treatment after a defined period if eligible.

The integrated program was designed primarily to assess safety, tolerability, biomarker changes and preliminary efficacy. It was not originally powered like a conventional Phase III randomized trial. That design is the origin of both the program’s opportunity and its regulatory controversy.

07 The AMT-130 efficacy narrative

September 29, 2026 update. Updated 36-month analysis, high dose n=15. Mean cUHDRS change was −0.28 versus −1.39 in the updated ENROLL-HD comparator, reported as 80% slowing (nominal p=0.005). Mean TFC change was −0.27 versus −0.82, or 67% slowing (nominal p=0.011). CSF neurofilament light was 6% below baseline in 14 patients. These are comparisons with an external natural-history group, not a contemporaneous randomized estimate of treatment benefit.

Prespecified 48-month analysis, high dose n=12. Mean cUHDRS change was −0.90 versus −1.61, a reported 44% slowing with p=0.144: the primary endpoint did not reach statistical significance. TFC changed −0.37 versus −0.94, a 61% slowing with nominal p=0.008. CSF neurofilament light was 4% above baseline in 11 patients. The functional result and biomarker sit alongside a missed primary endpoint.

Comparator sensitivity. The updated ENROLL-HD dataset has a September 2025 cutoff and the matched high-dose comparator comprises 1,337 participants. Missing control observations reached 53% at 48 months. uniQure believes differential attrition and survivor bias understate control decline; that is the company’s interpretation. A post-hoc analysis against the prior comparator yielded 53.5% cUHDRS slowing (nominal p=0.041) and 68.3% TFC slowing (nominal p=0.001). Changing the comparator after the fact is a sensitivity check, not a replacement for the prespecified primary result. Company source

The cUHDRS combines total motor score, symbol digit modalities, Stroop word reading and Total Functional Capacity. Because Huntington’s affects multiple domains, a composite can be more sensitive to overall change than a single measure. Total Functional Capacity is especially clinically meaningful because it reflects a patient’s ability to work, manage finances, perform domestic tasks and live independently.

Historical reference: the earlier three-year analysis was described as approximately 75% cUHDRS slowing. The September 29 update uses additional follow-up and an updated comparator, reporting 80% at 36 months and 44% at 48 months; the latter primary comparison is not statistically significant. These percentages come from different analyses and do not combine into one figure. September 29 source

Sell-side views moved after the four-year data. On October 5, 2026 Barclays downgraded uniQure from Overweight to Equal Weight, a rating it had raised in June. Report According to Dow Jones Newswires, Barclays also lowered its price target to $28 from $60. A rating or target change is a broker’s opinion on relative return that reflects its own assumptions; it does not alter the submitted application, which uniQure says remains based on the 36-month dataset, nor the absence of a new FDA action date. Barclays’ rationale is not publicly available; the timing, one week after the September 29 release, is the only link that can be stated.

08 Safety profile and the 2022 pause

September 29, 2026 update. The release reiterates five previously disclosed high-dose participants with treatment-related serious adverse events involving CNS inflammation, all resolved. It also reports a suicide in a low-dose patient about five years after treatment, assessed as unrelated by the investigator. That attribution stands, but it is not proof of zero long-term risk. Procedure, neuroinflammation and prolonged follow-up remain relevant. Company source

AMT-130 requires invasive neurosurgery and direct brain infusion, so safety must be divided into procedure-related events and vector-related biology. Common adverse events have included effects associated with surgery and hospitalization. In 2022, uniQure voluntarily paused enrollment after suspected unexpected serious adverse reactions in three European patients, including neurological complications.

The company conducted a safety review, modified management procedures and resumed enrollment. Later follow-up suggested that the safety profile was manageable, with no new drug-related serious adverse events reported after December 2022 through the company’s later updates.

This history is relevant for two reasons. First, AMT-130 has already survived a significant clinical safety review and continued development. Second, a commercial label may require detailed risk management around surgery, immunosuppression, imaging, neurological monitoring and center qualification.

Accelerated approval would not eliminate the need for long-term observation. Patients receiving integrating or persistent genetic interventions are followed for years. uniQure must monitor potential neuroinflammation, changes related to non-selective huntingtin lowering, vector durability and any delayed neurological consequences.

09 Regulatory timeline: from alignment to shock to reversal

AMT-130 also has FDA Fast Track designation, as stated in uniQure’s September 2 BLA announcement. uniQure press release on the Biologics License Application submission.

June 2024 — RMAT designation FDA granted Regenerative Medicine Advanced Therapy status based on the potential to address major unmet need and interim clinical evidence.
December 2024 — initial accelerated-approval alignment Following a Type B meeting, uniQure said FDA agreed that Phase I/II data compared with natural-history controls could potentially serve as the primary basis of a BLA.
April 2025 — Breakthrough Therapy designation FDA added another expedited designation, reinforcing the perception that the program had a viable early filing path.
October–December 2025 — pre-BLA reversal After the pre-BLA meeting, FDA stated that the submitted Phase I/II dataset was currently unlikely to provide the primary evidence required for a BLA.
January–March 2026 — Type A meeting and deeper rejection FDA said it could not agree that external-control data were sufficient primary effectiveness evidence and strongly recommended a prospective randomized, double-blind, sham-surgery-controlled study.
June 17, 2026 — Type B reversal FDA communicated that the three-year Phase I/II analysis would be acceptable as the primary basis of a BLA for accelerated approval, subject to alignment on a confirmatory study.
Q3 2026 — done uniQure submitted the U.S. BLA and the U.K. MAA on September 2, 2026, with priority review requested.

What matters now is the written and operational outcome, not speculation about internal agency politics. The June 2026 disclosure was incorporated into a securities filing: FDA stated that the three-year analysis could serve as the primary BLA basis. That is a meaningful regulatory fact. It is not an approval promise.

10 The confirmatory-study requirement

Alignment with uniQure on the confirmatory study design was sought by the FDA before submission and, on the company’s July 29, 2026 description, those discussions were underway. The agency is considering a concurrent standard-of-care control that would not include a sham surgical procedure. The company reported that FDA expects the study to be well underway, and potentially fully enrolled, at accelerated approval; full enrollment was not stated as an unconditional requirement.

An accelerated-approval pathway would require verification of clinical benefit. Confirmatory execution is therefore a substantive condition, not a substitute for evaluating the externally controlled Phase I/II evidence.

A non-sham concurrent control could be more ethical and easier to enroll than a blinded sham-neurosurgery trial. Patients would know whether they received gene therapy, however, which may introduce assessment bias. The design must address endpoint objectivity, site effects, baseline balance and the timing of crossover or rescue treatment.

The most important near-term questions are:

• What enrollment, control group, endpoint and follow-up will FDA accept?
• What progress must be demonstrated by the action date?
• How would recruitment continue alongside a potential commercial launch?

Key regulatory distinction: alignment on a BLA basis does not equal filing acceptance, priority review, advisory-committee avoidance or approval. Each of those remains a separate step.

11 U.S. BLA and UK MAA strategy

September 29, 2026 update. According to uniQure, at the June 2026 Type B meeting FDA said the original 36-month data from 12 high-dose patients would be acceptable as the primary basis for a BLA submission under accelerated approval. The new 36- and 48-month analyses were not included in that submitted BLA. Acceptability as a submission basis is distinct from filing acceptance, benefit-risk review and an approval decision. The company identifies TFC as the primary measure of its confirmatory study; actual regulatory alignment and execution remain separate evidence. Company source

uniQure submitted the U.S. BLA for AMT-130 on September 2, 2026, seeking accelerated approval. A complete submission must include clinical data, external-control analyses, manufacturing validation, device and surgical procedure information, long-term follow-up plans, proposed labeling and confirmatory-study documentation.

The company submitted the U.K. Marketing Authorisation Application to the MHRA on the same day, September 2, 2026, after a pre-submission meeting with the agency. The UK pathway provides regulatory diversification. A favorable UK review could create the first commercial market even if the U.S. path slows, while a negative outcome could expose shared concerns about evidence or manufacturing.

European Union strategy is less clearly defined in current guidance. Huntington’s disease is a global market, but sequential regulatory submissions may be necessary because uniQure must allocate resources to the U.S., UK, confirmatory study and launch preparation.

The filing is done; BLA acceptance is now the event that matters. uniQure has requested priority review, which on the company’s description would produce a six-month review cycle following the FDA’s 60-day filing review period. Until the agency accepts the application there is no target action date, and no advisory committee has been announced. A public AdCom could amplify debate over external controls, clinical meaningfulness, durability and surgical risk.

12 Commercial opportunity and launch architecture

Huntington’s disease is rare but not ultra-rare. The diagnosed population across the U.S. and Europe is large enough to support a substantial specialized product if clinical benefit is accepted. Mutation carriers can be identified through genetic testing, but the initial AMT-130 label is likely to focus on early manifest patients matching the clinical program.

The product would require treatment at qualified neurosurgical centers. Commercial adoption depends on a coordinated pathway involving neurologists, genetic counselors, imaging, neurosurgery, hospital pharmacy, payer approval and long-term follow-up. The number of treatment centers may be limited initially, which can create a bottleneck but also keeps the commercial organization focused.

Pricing is unknown. One-time neurological gene therapies can support high prices, but payers will scrutinize durability, procedure risk and the uncertainty of accelerated approval. Outcomes-based agreements or staged payments may be considered, particularly if the confirmatory study is incomplete at launch.

The launch curve may be shaped by a backlog of well-characterized early manifest patients, followed by slower steady-state referrals. Some patients may delay treatment because of the invasive procedure, irreversible dosing and uncertainty about long-term wild-type huntingtin lowering. Others may accept meaningful risk because the disease is progressive and no disease-modifying alternative exists.

Commercial advantage

No approved disease-modifying therapy and a genetically defined patient population.

Commercial friction

Neurosurgery, center capacity, payer review and irreversible one-time dosing.

Key adoption variable

Whether clinicians view the three-year slowing as clinically meaningful and sufficiently reliable.

13 Manufacturing and delivery risk

AMT-130 manufacturing requires consistent AAV5 vector production, validated potency assays, control of capsid quality and reproducible fill-finish. The BLA must demonstrate that clinical material is comparable to the intended commercial process.

uniQure has deep AAV manufacturing experience, but its operating model changed after divestitures and restructuring. The company transferred a Lexington manufacturing facility and later reworked relationships with Genezen and CSL Behring. HEMGENIX supply commitments are transitioning to a direct CSL–Genezen relationship, reducing uniQure’s operational burden but also changing the internal manufacturing footprint.

The administration procedure is equally important. Catheter placement, MRI guidance, infusion rate and targeting must be standardized across centers. A therapy can have an approved vector yet fail commercially if procedural variability produces inconsistent distribution or unacceptable complications.

Center certification and surgeon training may therefore become part of the label and risk-management plan. This creates a high barrier to entry, but also limits the speed of launch.

14 Financial position and dilution framework

The financing record includes Amendment No. 4 to the Hercules loan agreement dated July 27, 2026. The July 29 filing identifies Matthew Kapusta as CEO and Christian Klemt as CFO. Exhibit 10.2 to uniQure’s Q2 2026 Form 10-Q; uniQure Q2 2026 Form 10-Q.

The ownership record includes dated disclosures for Aberdeen (4.52%), JPMorgan (7.0%), RTW (5.7%) and Susquehanna-related entities (4.8%). RTW had already reported a 4.1% stake as of March 31, 2026; the later filing reflects an increase to 5.7%. Form 4 filings submitted in July for Kapusta, Walid Abi-Saab and Jack Kaye report transactions under pre-existing Rule 10b5-1 plans; Kapusta’s Form 144 notice covers the same 21,082 shares reported on his Form 4. SEC EDGAR filing 1; SEC EDGAR filing 2; SEC EDGAR filing 3; SEC EDGAR filing 4; SEC EDGAR filing 5; SEC EDGAR filing 6; SEC EDGAR filing 7; SEC EDGAR filing 8; SEC EDGAR filing 9.

The June equity offering increased liquidity and the share base. The $495.1 million royalty-financing carrying liability includes $489.3 million noncurrent and $5.8 million current. It is distinct from the $50 million Hercules loan: payments derive from transferred royalties, and the agreement does not require repayment of a shortfall if its cap is not reached during the term. Subtracting the whole accounting liability from cash as equivalent term debt would misrepresent these economics.

The runway into 2030 is based on the current operating plan. A confirmatory Huntington’s study, regulatory submissions, manufacturing scale-up, launch preparation and larger AMT-260 or AMT-191 studies can push spending higher. The balance sheet materially lowers near-term financing risk, but dilution remains a central per-share variable.

Who reported a position in the middle of August

Two Schedule 13G filings landed on August 14, 2026, both describing holdings as of June 30 and therefore capturing the register immediately after the June follow-on rather than as of this update.

RTW Investments, with Roderick Wong, reported 3,941,572 ordinary shares, 5.7% of the class, on a new Schedule 13G. A filing reporting ownership above the 5% threshold from a healthcare-dedicated manager sits in a different category from an index position, and the holding was in place at a point when the BLA submission was guided but not filed. The filing itself says nothing about why the position was taken.

G1 Execution Services, part of the Susquehanna group of affiliated broker-dealers, reported 3,339,231 aggregate beneficial shares including options, 4.8%, on an amended filing. The filing notes that G1 Execution Services, SIG Brokerage and Susquehanna Securities are affiliated independent broker-dealers which, together with two further Susquehanna entities, may be deemed a group. Broker-dealer inventory and a discretionary investment position are not the same kind of holding, and the filing does not state which this is.

The reported ownership percentages are rounded and do not allow an exact share-count denominator or the timing of offering settlement to be inferred. These quarter-end holdings were filed later and do not establish subsequent transactions or investment intent.

The Q2 10-Q also discloses an amended securities-class-action complaint filed July 15. A motion-to-dismiss deadline was set for September 14, 2026, and the company had not accrued a liability. This is not the core valuation driver, but it belongs in the risk map.

15 HEMGENIX legacy: proof of capability, limited economics

HEMGENIX, originally developed by uniQure as etranacogene dezaparvovec, is an approved AAV5 gene therapy for hemophilia B. CSL Behring acquired global commercialization rights through a major licensing transaction.

The program validates uniQure’s ability to design and develop an AAV therapy that reaches approval. It also provides regulatory and manufacturing credibility when evaluating AMT-130. However, investors should not model HEMGENIX as if uniQure retained full product economics.

In May 2023, uniQure entered into a royalty-financing agreement with HemB SPV, L.P. and received $375 million upfront in exchange for rights to the lowest royalty tier on certain current and future HEMGENIX net sales. uniQure retained other contractual economics, including certain milestone rights and royalty participation outside the transferred tier. In 2026, agreements with CSL and Genezen ended uniQure’s remaining supply and minimum-purchase commitments after delivery of specified batches, with CSL moving to a direct Genezen supply relationship.

This simplifies uniQure’s operations and removes manufacturing obligations that no longer fit the AMT-130-centered strategy. HEMGENIX is best seen as platform validation and modest legacy economics—not the primary source of future value.

16 AMT-260 in refractory mesial temporal lobe epilepsy

AMT-260 is a gene-silencing therapy for refractory mesial temporal lobe epilepsy. The program uses an AAV9 vector carrying microRNA designed to suppress aberrant expression of GRIK2, which encodes the GluK2 subunit of kainate receptors in the hippocampus.

Refractory MTLE can cause frequent seizures, cognitive decline, injury and reduced life expectancy. Surgical resection or laser ablation may help some patients, but only a small percentage of eligible patients undergo surgery. AMT-260 seeks to reduce pathological excitability without removing brain tissue.

uniQure acquired the program through Corlieve Therapeutics in 2021. The GenTLE Phase I/IIa study has an open-label dose-escalation part followed by an expected randomized proof-of-concept component. The first cohort included six patients, and enrollment in a second six-patient cohort was underway in 2026.

The Q2 update broadened the first-cohort picture beyond the initial single patient. Three of six low-dose patients had 79%–100% reductions in disabling seizures during months 4–6, while the other three ranged from a 33% reduction to a 36% increase. The dispersion is both the signal and the warning: activity may be meaningful in responders, but six uncontrolled patients cannot establish efficacy. The July 29, 2026 update guided completion of cohort 2 enrollment to Q3 2026 and new results to the first half of 2027; that guidance alone does not confirm enrollment completion, and no related serious adverse events had been reported.

AMT-260’s clinical case could strengthen if multiple patients show durable reductions in seizure frequency, reduced antiseizure-medication burden and preserved cognitive function. Safety is also critical because the treatment requires direct brain delivery in patients who may otherwise consider established surgical options.

17 AMT-191 in Fabry disease

AMT-191 is a liver-directed AAV5 gene therapy carrying the GLA transgene under a potent liver-specific promoter. The objective is sustained production of alpha-galactosidase A, the enzyme deficient in Fabry disease.

Fabry disease is an X-linked lysosomal storage disorder characterized by accumulation of globotriaosylceramide and related substrates. Patients can develop kidney failure, cardiomyopathy, arrhythmia, neuropathic pain and stroke. Enzyme-replacement therapy requires repeated infusions and may not fully prevent organ progression.

Q2 data continued to show dose-dependent alpha-Gal A expression across eleven treated patients, and all eleven had discontinued enzyme-replacement therapy. However, enrollment at the middle and high doses remains paused after two mid-dose patients developed Grade 3 liver-enzyme dose-limiting toxicities. The elevations resolved by the end of May after immunosuppression. The biomarker effect is real, but dose selection and hepatic safety now dominate the program. Five serious adverse events had previously been reported in two highest-dose patients.

The program therefore demonstrates strong biological activity but has not established an optimal dose. If a lower dose can maintain sufficient enzyme activity without significant liver toxicity, AMT-191 could remain competitive. If high expression requires a dose with unacceptable hepatotoxicity, the program’s value may be limited despite impressive laboratory numbers.

18 AMT-162 discontinuation and what it teaches

AMT-162 was an intrathecal gene therapy designed to lower SOD1 in patients with SOD1-mutated amyotrophic lateral sclerosis. uniQure licensed the program from Apic Bio and initiated the EPISOD1 Phase I/II study.

Enrollment was voluntarily paused in 2025 after an independent monitoring review identified a serious adverse event that qualified as a dose-limiting toxicity in the second cohort. After review of preliminary safety and efficacy data from the five treated patients, uniQure discontinued development in 2026.

The discontinuation removes a potentially expensive program with weak risk-adjusted prospects. It also demonstrates that not every gene-silencing construct or intrathecal AAV strategy will produce a workable therapeutic window. For investors, AMT-162 should be excluded from forward pipeline value and retained only as a reminder of platform risk.

19 Competitive landscape in Huntington’s disease

Novartis’s INVEST-HD trial (NCT07326709) is a randomized, placebo-controlled Phase 3 study of oral votoplam. The September 22, 2026 registry update lists recruiting status, an estimated 770 participants and estimated primary completion in April 2030. It is a competing development program, not proof of clinical success. ClinicalTrials.gov record NCT07326709; Novartis clinical trial page for NCT07326709.

The Huntington’s field includes multiple approaches to lower huntingtin or modify disease biology. Antisense oligonucleotides, RNA interference, small molecules, allele-selective strategies and other gene therapies are being explored.

Roche and Ionis experienced a major setback with tominersen when a Phase III program was stopped for unfavorable benefit-risk, although revised lower-frequency strategies continued to be investigated. Wave Life Sciences is developing allele-selective oligonucleotides intended to lower mutant huntingtin while preserving wild-type protein. Other companies are exploring orally available splicing modulators or different RNA-targeting technologies.

AMT-130’s differentiation is durability. A one-time treatment could avoid repeated lumbar punctures or chronic dosing. Its disadvantages are neurosurgery, irreversible exposure and non-selective huntingtin lowering.

If approved first, AMT-130 could establish treatment centers and physician familiarity before competitors mature. However, a later therapy with safer administration, allele selectivity or stronger randomized evidence could challenge adoption. Commercial success therefore depends not only on first approval but on durability, real-world benefit and the competitive timeline.

20 Catalyst map

21 Risk matrix

September 29, 2026 update. The 53% missingness in the 48-month external control and the difference between prespecified and post-hoc conclusions are now observed methodological issues. Small treated cohorts limit precision. A non-significant result does not prove absence of effect, but it prevents presenting the primary analysis as statistically confirmed. Nominal p-values for secondary and sensitivity analyses do not resolve multiplicity or selection concerns. Company source

22 Related Merlintrader coverage

• uniQure: FDA says AMT-130 data are not enough and recommends a sham-controlled study
• uniQure: FDA reversal puts AMT-130 back on the accelerated-approval path
• Merlintrader Biotech Stocks Hub 2026